Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change

Rhea-AI Summary

Trinity Biotech Plc. (TRIB) has finalized a ratio change for its American depositary shares (ADSs) from 1 ADS representing 4 Class A ordinary shares to 1 ADS representing 20 Class A ordinary shares. The change aims to comply with the $1.00 Nasdaq minimum bid price requirement and maintain its NASDAQ listing.

Financial Analyst

The adjustment in the ADS ratio by Trinity Biotech Plc is a strategic move aimed at addressing the Nasdaq's minimum bid price requirement. This action, effectively a reverse stock split, is often employed by companies facing delisting threats due to their stock trading below the $1 threshold. By consolidating shares, the company hopes to elevate its share price above this level, thereby meeting Nasdaq's standards and retaining its listing status.

From a financial perspective, while the intrinsic value of the company remains unchanged, the optics of a higher share price can sometimes be perceived positively by the market. However, investors should be aware that such maneuvers do not address underlying business performance issues, if any and should evaluate the company's fundamentals when considering the long-term impact of this action.

Market Research Analyst

Market perception of reverse stock splits is mixed. On one hand, it can be seen as a company taking proactive steps to comply with trading requirements, potentially avoiding the negative stigma associated with trading on a lower-tier exchange. On the other hand, it can also be perceived as a sign of trouble, indicating that the company has been unable to organically boost its share price through performance.

For Trinity Biotech Plc, the market's reaction will depend on the confidence investors have in the company's future growth prospects. It is essential for stakeholders to monitor the company's subsequent financial results and strategic initiatives to assess whether the reverse split will serve as a temporary fix or part of a broader turnaround strategy.

Securities Compliance Expert

The reverse stock split is a compliance tactic to adhere to Nasdaq's listing requirements, specifically the $1.00 minimum bid price. This regulatory measure ensures a certain standard for companies listed on this prestigious exchange. For Trinity Biotech Plc, maintaining its Nasdaq listing is crucial as it provides access to a broad base of institutional and retail investors, which can be beneficial for future capital raising endeavors and overall liquidity of the stock.

However, it's important to note that this is a remedial measure and does not directly reflect on the company's operational health. Compliance with exchange requirements is a basic necessity for listed entities and investors should not consider it as an indicator of financial performance or growth potential.

DUBLIN, Ireland, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.(NASDAQ: TRIB) (the “Company”) today announced that it has finalized the effective date of its ratio change of its American depositary shares (“ADSs”) from one (1) ADS representing four (4) Class A ordinary shares to one (1) ADS representing twenty (20) Class A ordinary shares. The effect of the ratio change on the ADS trading price on the Nasdaq Global Market is expected to take place at the open of trading on February 23, 2024 (U.S. Eastern Time) (the “Effective Date”).

For Trinity Biotech Plc ADS holders, the change in the ADS ratio on February 23, 2024 will have the same effect as a one-for-five reverse ADS split and is intended to enable the Company to regain compliance with the $1.00 Nasdaq minimum bid price requirement and maintain its NASDAQ listing.

Other than the change of effective date to February 23^rd, 2024, the remaining details regarding the ratio change remain the same as previously announced on February 13, 2024.

About Trinity Biotech Plc

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.

Forward Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterised by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this presentation may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on our purchase of the assets of Waveform, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2022 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Contact:		Trinity Biotech plc		Eric Ribner
		Des Fitzgerald		LifeSci Advisors, LLC
		+353-1-2769800		+1-646 -751-4363
				E-mail: investorrelations@trinitybiotech.com

What is the ratio change announced by Trinity Biotech Plc. (TRIB)?

Trinity Biotech Plc. (TRIB) announced a ratio change for its American depositary shares (ADSs) from 1 ADS representing 4 Class A ordinary shares to 1 ADS representing 20 Class A ordinary shares.

When will the ratio change be effective for Trinity Biotech Plc. (TRIB) ADS holders?

The ratio change for Trinity Biotech Plc. (TRIB) ADS holders will be effective on February 23, 2024.

What is the purpose of the ratio change announced by Trinity Biotech Plc. (TRIB)?

The ratio change announced by Trinity Biotech Plc. (TRIB) aims to enable the Company to comply with the $1.00 Nasdaq minimum bid price requirement and maintain its NASDAQ listing.